Departments of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan Province, China.
Sci Rep. 2023 Oct 6;13(1):16859. doi: 10.1038/s41598-023-43699-2.
Worldwide, cancer is a huge burden, and each year sees an increase in its incidence. RAB (Ras-related in brain) 13 is crucial for a number of tumor types. But more research on RAB13's tumor-related mechanism is still required. This study's goal was to investigate RAB13's function in human pan-cancer, and we have also preliminarily explored the relevant mechanisms. To investigate the differential expression, survival prognosis, immunological checkpoints, and pathological stage of RAB13 in human pan-cancer, respectively, databases of TIMER2.0, GEPIA 2, and UALCAN were employed. CBioPortal database was used to analyze the mutation level, meanwhile, PPI network was constructed based on STRING website. The putative functions of RAB13 in immunological infiltration were investigated using single sample gene set enrichment analysis (ssGSEA). The mechanism of RAB13 in hepatocellular cancer was also briefly investigated by us using gene set enrichment analysis (GSEA). RAB13 was differentially expressed in a number of different cancers, including liver hepatocellular carcinoma (LIHC), stomach adenocarcinoma (STAD), etc. Additionally, RAB13 overexpression in LGG and LIHC is associated with a worse prognosis, including overall survival (OS) and disease-free survival (DFS). Then, we observed that early in BLCA, BRAC, CHOL, ESCA, HNSC, KICH, KIRC, LIHC, LUAD, LUSC, and STAD, the level of RAB13 expression was raised. Next, we found that "amplification" was the most common mutation in RAB13. The expression of SLC39A1, JTB, SSR2, SNAPIN, and RHOC was strongly positively linked with RAB13, according to a correlation study. RAB13 favorably regulated B cell, CD8 + T cell, CD4 + T cell, macrophage, neutrophil, and dendritic cell in LIHC, according to immune infiltration analysis. Immune checkpoint study revealed a positive correlation between RAB13 expression and PD1, PDL1, and CTLA4 in LIHC. According to GSEA, RAB13 is involved in a number of processes in LIHC, including MTORC1 signaling, MYC targets v1, G2M checkpoint, MITOTIC spindle, DNA repair, P53 pathway, glycolysis, PI3K-AKT-MTOR signaling, etc. RAB13 is a possible therapeutic target in LIHC and can be used as a prognostic marker.
在全球范围内，癌症是一个巨大的负担，每年的发病率都在增加。RAB（Ras-related in brain）13 对许多肿瘤类型都至关重要。但仍需要更多的研究来探索 RAB13 与肿瘤相关的机制。本研究的目的是探讨 RAB13 在人类泛癌中的作用，我们还初步探讨了相关机制。为了分别研究 RAB13 在人类泛癌中的差异表达、生存预后、免疫检查点和病理分期，我们使用了 TIMER2.0、GEPIA 2 和 UALCAN 数据库。使用 CBioPortal 数据库分析突变水平，同时使用 STRING 网站构建 PPI 网络。使用单样本基因集富集分析（ssGSEA）研究 RAB13 在免疫浸润中的可能功能。我们还使用基因集富集分析（GSEA）简要研究了 RAB13 在肝细胞癌中的作用机制。RAB13 在多种不同的癌症中表达差异，包括肝癌（LIHC）、胃腺癌（STAD）等。此外，RAB13 在 LGG 和 LIHC 中的高表达与较差的预后相关，包括总生存（OS）和无病生存（DFS）。然后，我们观察到在 BLCA、BRAC、CHOL、ESCA、HNSC、KICH、KIRC、LIHC、LUAD、LUSC 和 STAD 的早期，RAB13 的表达水平升高。接下来，我们发现“扩增”是 RAB13 最常见的突变。根据相关性研究，SLC39A1、JTB、SSR2、SNAPIN 和 RHOC 的表达与 RAB13 呈强烈正相关。在 LIHC 中，RAB13 可以正向调节 B 细胞、CD8+T 细胞、CD4+T 细胞、巨噬细胞、中性粒细胞和树突状细胞。免疫浸润分析显示，RAB13 与 LIHC 中的 PD1、PDL1 和 CTLA4 表达呈正相关。根据 GSEA，RAB13 参与了 LIHC 中的许多过程，包括 MTORC1 信号、MYC targets v1、G2M 检查点、MITOTIC 纺锤体、DNA 修复、P53 通路、糖酵解、PI3K-AKT-MTOR 信号等。RAB13 可能是 LIHC 的一种治疗靶点，可以作为预后标志物。
